联合免疫检查点抑制剂与铂类-埃托波诺司德是广泛期小细胞肺癌（ES-SCLC）患者标准的一线治疗。导致化疗免疫治疗在ES-SCLC中获得批准的III期临床试验排除了Eastern Cooperative Group (ECOG)2-3级的患者。因此，关于ECOG2-3级患者化疗免疫治疗的疗效数据有限。对在Mayo Clinic Health System接受化疗免疫治疗（atezolizumab或durvalumab）的ES-SCLC诊断患者进行了回顾性分析，研究目的是比较接受新诊断ES-SCLC的化疗免疫治疗的ECOG 0-1级患者和ECOG 2-3级患者在整体生存期（OS）、无进展生存期（PFS）和最佳临床治疗反应方面的差异。 共有82名患者被纳入研究。平均年龄±标准差为68.1±8.3岁。其中，56例患者被识别为ECOG 0-1级，26例患者被识别为ECOG 2-3级。无论ECOG级别如何，中位PFS相似（ECOG 0-1组5.8个月[95% CI，4.3-6.0个月] vs. ECOG 2-3组4.1个月[95% CI，3.8-6.9个月]; p = .2994）。无论ECOG级别如何，中位OS也相似（ECOG 0-1组10.6个月[95% CI，8.4-13.4个月] vs. ECOG 2-3组9.3个月[95% CI，4.9-12.8个月]; p = .2718）。研究结果表明，ECOG 2-3组和ECOG 0-1组的PFS和OS没有显著差异。因此，对于具有ECOG 2-3级的ES-SCLC患者应考虑化疗免疫治疗。 © 2023美国癌症协会。

Immune checkpoint inhibitor combined with platinum-etoposide is the standard first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). The phase 3 clinical trials that led to the approval of chemoimmunotherapy in ES-SCLC excluded patients who had an Eastern Cooperative Group (ECOG) performance status (PS) of 2-3. Therefore, data on the efficacy of chemoimmunotherapy in patients with an ECOG PS of 2-3 are limited.A retrospective analysis was performed on patients diagnosed with ES-SCLC who received chemoimmunotherapy (atezolizumab or durvalumab) within the Mayo Clinic Health System between January 2016 and January 2021. The objective of this study was to compare the overall survival (OS), progression-free survival (PFS), and best clinical response to therapy in patients with an ECOG PS of 0-1 vs. patients with an ECOG PS of 2-3 who received chemoimmunotherapy for newly diagnosed ES-SCLC.In total, 82 patients were included in the study. The mean ± standard deviation age was 68.1 ± 8.3 years. Of these, 56 patients were identified with an ECOG PS of 0-1, and 26 patients were identified with an ECOG PS of 2-3. The median PFS was similar regardless of ECOG PS (5.8 months [95% CI, 4.3-6.0 months] in the ECOG PS 0-1 group vs. 4.1 months [95% CI, 3.8-6.9 months] in the ECOG PS 2-3; p = .2994). The median OS was also similar regardless of ECOG PS (10.6 months [95% CI, 8.4-13.4 months] in the ECOG PS 0-1 group vs. 9.3 months [95% CI, 4.9-12.8 months]; p = .2718) in the ECOG PS 2-3 group.The study results demonstrated no significant difference in PFS or OS among the ECOG PS 2-3 and ECOG PS 0-1 groups. Therefore, chemoimmunotherapy should be considered for patients who have ES-SCLC with an ECOG PS of 2-3.© 2023 American Cancer Society.